Skip to main content
Rocco Crescenzo, DO, Oncology, Plymouth Meeting, PA

RoccoJCrescenzoDO

Oncology Plymouth Meeting, PA

Physician

Dr. Crescenzo is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Crescenzo's full profile

Already have an account?

Education & Training

  • Sidney Kimmel Medical College at Thomas Jefferson University/TJUH
    Sidney Kimmel Medical College at Thomas Jefferson University/TJUHFellowship, Hematology and Medical Oncology, 1996 - 1999
  • Philadelphia College of Osteopathic Medicine
    Philadelphia College of Osteopathic MedicineInternship, Transitional Year, 1992 - 1993
  • Philadelphia College of Osteopathic Medicine
    Philadelphia College of Osteopathic MedicineClass of 1992
  • La Salle University
    La Salle UniversityB.A., Biology, English, 1983 - 1987

Certifications & Licensure

  • PA State Medical License
    PA State License 1993 - 2020
  • AOA Board of Internal Medicine Addiction Medicine (CAQ)
  • American Osteopathic Bboard of Internal MedicineMedical Oncology

Awards, Honors, & Recognition

  • Teacher of the Year PCOM, 2008, 2012
  • Fellow ACOI
  • Sigma Sigma Phi PCOM
  • Join now to see all

Publications & Presentations

PubMed

Journal Articles

  • Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial  
    Floquet A, Vergote I, Colombo N, Fiane B, Monk BJ, Reinthaller A, Calvert P, Herzog TJ, Meier W, Kim JW, del Campo JM, Friedlander M, Pisano C, Isonishi S, Crescenzo R..., Gynecol Oncol, 1/1/2015
  • An Immunological Analysis of Mesodermal Myogenic and Connective Tissue Precursors of the Chick Embryo  
    Crescenzo RJ, Journal of Cell Biology, 1/1/1990
  • Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA31 (lapatinib vs trastuzumab)  
    Crescenzo RJ, Breast Cancer Research

Books/Book Chapters

Abstracts/Posters

  • Bosutinib vs. imatinib for newly diagnosed chronic myeloid leukemia (CML) in the BFORE trial: results by 3-month BCR-ABL1 transcript level.
    Crescenzo RJ, ESH-iCMLF, 1/1/2017
  • Breast ultrasound and mammography and response to neoadjuvant lapatinib, trastuzumab and their combination in HER2 positive breast cancer: results from Neo-ALTTO (BIG ...
    Serena Di Cosimo, Christine Campbell , Hatem A. Azim Jr., Giuseppe Curigliano, Carmen Criscitiello, Rocco J Crescenzo, Martine J. Piccart-Gebhart, Holger Eidtmann, Jos..., SABC, 1/1/2015
  • HLA-DRB1*7:01 Biomarker Characterization of Hepatotoxicity During Lapatinib Combination Therapies in ALTTO
    Spraggs C, Parham L, Liling W, Williams L, Briley LP, Fraser DJ, Aziz Z, Tong Z, Moodley S, Mehta AO, Jackson N, Byrne J, Andersson M, Toi M, Harris L, Gralow JR, Cres..., Abstract 617 ASCO, 1/1/2015
  • Join now to see all

Lectures

  • Infections in post-Bone Marrow Transplant Patients 
    Hershey Lodge and Convention Centre, Hershey, PA, 2004, 2007, 2009, 2012 - 1/1/2012
  • Use of TKI in Renal and Ovarian cancer 
    Multiple Locations, 2008, 2009, 2011 - 1/1/2011
  • Angiogenesis inhibitors in ovarian cancer 
    Hershey, PA - 1/1/2010
  • Join now to see all

Other

  • Biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 blockade with chemotherapy plus trastuzumab and lapatinib as neoadjuvant therapy for ... 
    Crescenzo RJ, Clinical Cancer Research (Manuscript # CCR-14-2611)

Professional Memberships